3 Reasons to Avoid UTHR and 1 Stock to Buy Instead
FROM THE WIRE · FINANCE.YAHOO.COM
3 Reasons to Avoid UTHR and 1 Stock to Buy Instead Since April 2026, United Therapeutics has been in a holding pattern, posting a small loss of 4.2% while floating around $541.72. The stock also fell short of the S&P 500's 17.5% gain during that period. Is there a buying…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishUnited Therapeutics has underperformed the S&P 500 with weak revenue forecasts per analysts.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01United Therapeutics has posted a 4.2% loss since April 2026, while the S&P 500 gained 17.5%.
- 02The stock currently trades at $541.72 per share.
- 03Wall Street revenue forecasts signal weak prospects for the company over the next 12 months.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
United Therapeutics Corporation554.55 USD-0.31%today +2.39%Negative S&P 5007,793.33+0.03%today -0.33%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets